Gov. Charlie Baker on Friday signed a $623-million life sciences bond bill to provide funding for education, research and development and workforce training for the industry.
A Harvard Bioscience subsidiary has launched a new inhalation and exposure system for drug research amid rising popularity of drugs taken respiratorily.
Littleton imaging device company Mevion Medical Systems has closed on $150 million in financing primarily from a Chinese pharmaceutical investment firm and private equity investors.
The Michigan medical device rival of Marlborough's Boston Scientific said Wednesday it is not in talks to acquire the Massachusetts company despite a report of a potential takeover.
Pharmaceutical law expert Jeffrey Wiesen has been appointed to the board of directors for Southborough-based Amorsa Therapeutics, the neuropharmaceutical firm announced Friday.
A former Bank of America executive who helped the company secure millions in foreign investments has been named the new president of Biostage in Holliston.
Biostage has named another Chinese executive to its board of directors as it seeks to remake itself and explore new markets in different parts of the world.